TABLE 3.
Adverse Events Occurring in ≥10% of Patients Treated with Obatoclax and Docetaxel in Phase 1 and Phase 2
| Treatment-Emergent Adverse Events, n (%) | Phase 1 N = 18 |
Phase 2 N = 32 |
||
|---|---|---|---|---|
| All Grades | Grade 3 or 4 | All Grades | Grade 3 or 4 | |
| ≥1 Event | 18 (100.0) | 15 (83.3) | 32 (100.0) | 20 (62.5) |
| Hematologic | ||||
| Anemia | 10 (55.6) | — | 15 (46.9) | 2 (6.3) |
| Neutropenia | 10 (55.6) | 10 (55.6) | 12 (37.5) | 10 (31.3) |
| Febrile neutropenia | 3 (16.7) | 3 (16.7) | 5 (15.6) | 5 (15.7) |
| Nonhematologic | ||||
| Fatigue | 9 (50) | — | 19 (59) | 2 (6) |
| Nausea | 7 (38.9) | — | 17 (53) | — |
| Dyspnea | 3 (16.7) | 2 (11.1) | 16 (50) | 6 (19) |
| Alopecia | 11 (61.1) | — | 14 (44) | — |
| Anorexia | 5 (27.8) | — | 13 (41) | — |
| Dizziness | 2 (11.1) | — | 11 (34) | — |
| Cough | 2 (11.1) | — | 9 (28) | 1 (3) |
| Constipation | 3 (16.7) | — | 8 (25) | — |
| Insomnia | — | — | 8 (25) | — |
| Diarrhea | 3 (16.7) | — | 7 (22) | — |
| Vomiting | 3 (16.7) | 1 (5.6) | 7 (22) | 1 (3) |
| Mucosal inflammation | — | — | 7 (22) | 1 (3) |
| Flushing | 2 (11.1) | — | 7 (22) | — |
| Ataxia | 3 (16.7) | — | 6 (19) | — |
| Pharyngolaryngeal pain | 7 (38.9) | — | 6 (19) | — |
| Dehydration | 5 (27.8) | — | 6 (19) | — |
| Peripheral edema | — | — | 5 (16) | — |
| Dysgeusia | 2 (11.1) | — | 5 (16) | — |
| Headache | 2 (11.1) | — | 5 (16) | — |
| Peripheral neuropathy | — | — | 5 (16) | — |
| Somnolence | — | — | 5 (16) | — |
| Confusional state | 4 (22.2) | — | 5 (16) | — |
| Euphoric mood | 4 (22.2) | — | 5 (16) | — |
| Back pain | 3 (16.7) | 1 (5.6) | 5 (16) | 2 (6) |
| Chills | 2 (11.1) | — | 4 (13) | — |
| Pyrexia | 3 (16.7) | — | 4 (13) | — |
| Anxiety | — | — | 4 (13) | — |
| Hallucinations | — | — | 4 (13) | 2 (6) |